Caring for
patients with
lymphoma?
Consider the
OLYMPIA studies
OLYMPIA studies
Caring for
patients with
lymphoma?
Consider the
OLYMPIA studies
OLYMPIA studies
With limited treatment options and no cure for lymphoma, the OLYMPIA clinical research studies are currently underway to evaluate the efficacy and safety of an investigational drug. Consider the OLYMPIA studies as an opportunity for your patients with lymphoma to access emerging treatments.
The investigational treatment is administered as an IV infusion. It is a bispecific antibody that binds to CD20, a B-cell surface antigen, and to the T-cell antigen CD3. The investigational treatment is designed to bridge CD20-expressing cells with cytotoxic T-cells by binding the CD3 subunit of the T-cell receptor, resulting in CD20-directed polyclonal T-cell killing of potentially cancerous B-cells.
The length of participation will depend on several factors, including which study a patient participates in and their response to treatment.
Participants may be reimbursed for reasonable costs related to their participation in the OLYMPIA studies, such as travel and food costs. Medical care related to participation, including the investigational study drug, will be provided at no cost. It may be necessary, however, for participants or health insurance providers to cover medical treatment that is considered the standard of care for lymphoma, such as chemotherapy, and for tests, medications, and supplies that are not required as part of the study.
How can you help?
The success of the OLYMPIA studies depends on physicians to refer potential study participants. Find out more about the OLYMPIA studies to see if your patients may be eligible.
For adults with follicular
lymphoma/marginal
zone lymphoma
The study team will review your patient’s full medical history to see if they meet all study inclusion criteria and none of the study exclusion criteria. Diversity in clinical studies is critical to developing better treatments – help ensure that your patients are represented in clinical research by talking to them about the OLYMPIA studies.
If you have potentially eligible and interested patients, empower them with options and discuss the OLYMPIA studies with them.
Your patient’s health and safety are our top priorities. We hope you value the impact of this research and will consider referring potential candidates. With your support, we hope to help patients with lymphoma.
English (Malaysia) 
English (United States) 
Korean 
Chinese (Taiwan) 
Malay 
Thai 
English (Australia) 
English (Israel) 
Spanish (Chile) 
Portuguese 
German (Austria) 
Italian 
Polish 
Spanish (Spain) 
Czech 
French (France) 
French (Belgium) 
Dutch 
English (Belgium) 
English (UK) 
German (Germany)